Valeant just got blindsided

The last week or so was supposed to be one of tiny tidbits of happy news for Valeant Pharmaceuticals, but the company was just blindsided, as the Food and Drug Administration raised concerns about one of its drug candidates.
The drug in question is glaucoma treatment latanoprostene bunod, and its approval was supposed to be a walk.
Every analyst on Wall Street was thinking about it that way. Even Valeant bear David Maris of Wells Fargo had the approval of all of these new drugs modeled into his